Author： Schmoor C. Schumacher M.
Publisher： Springer Publishing Company
ISSN： 0167-6806
Source： Breast Cancer Research and Treatment, Vol.54, Iss.1, 1999-03, pp. : 31-38
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer
By Antman K.H.
European Journal of Cancer, Vol. 37, Iss. 2, 2001-01 ,pp. :
Access to resources
Recommend
Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients
By Greinix Hildegard T. Linkesch Werner Seifert Manfred Kubista Ernst Czerwenka Klaus Elahi Fariborz Zielinski Christoph Hoecker Paul Steger Günther Schulenburg Axel Neumeister Geralt Rabitsch Werner Jakesz Raimund Kalhs Peter
Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. :
High-dose Chemotherapy in Tumours Other Than Lymphomas and Breast Cancer
European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. :
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
By Espinosa E. Morales S. Borrega P. Casas A. Madroñal C. Machengs I. Illarramendi J. Lizón J. Moreno J. Belón J. Janáriz J. Puente M. Checa T. Mel J. González Barón M.
Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. :